"The one that got the most attention on the post-earnings conference call was HyQvia, a long-acting version of Baxter's Gammagard, designed to replace immunoglobulin in patients with blood cancers or immunodeficiency syndromes. Baxter and its biotech partner Halozyme Therapeutics (HALO) won approval for HyQvia in the European Union in May, and are beginning to roll out the product in Germany and Scandinavia. The companies are still ironing out some regulatory issues with the U.S. Food and Drug Administration, but company executives say they hope for a mid-2014 launch."
Read More At Investor's Business Daily 7/19/13
Fezzi, you are such a believer in subcutaneous delivery, I couldn't agree more. What do you think of the injector market as a Sub-cut play? I think the biggest pure play in that sector is ATRS with their line of injectors, and their approaching PDUFA in October for Otrexup. That's my biggest position, although I have a good slice of HALO as well.
Sentiment: Strong Buy
Governments lay out the Gold to pay for healthcare around the world- So Governments apply the golden rule-" He who has the gold makes the rule"- and they will favor cheaper and "NONINFERIOR" (to IV) Subcut over IV.